165
Participants
Start Date
December 19, 2018
Primary Completion Date
February 14, 2020
Study Completion Date
February 14, 2020
Dupilumab
"Pharmaceutical form: solution,~Route of administration: SC"
Placebo
"Pharmaceutical form: solution,~Route of administration: SC"
Emollient (moisturizer)
"Pharmaceutical form: cream,~Route of administration: topical use"
Investigational Site Number 1560019, Beijing
Investigational Site Number 1560001, Beijing
Investigational Site Number 1560004, Beijing
Investigational Site Number 1560003, Beijing
Investigational Site Number 1560010, Beijing
Investigational Site Number 1560002, Shenyang
Investigational Site Number 1560005, Shenyang
Investigational Site Number 1560008, Shenyang
Investigational Site Number 1560021, Changchun
Investigational Site Number 1560016, Shanghai
Investigational Site Number 1560023, Shanghai
Investigational Site Number 1560018, Shanghai
Investigational Site Number 1560015, Shanghai
Investigational Site Number 1560022, Nanjing
Investigational Site Number 1560028, Wuxi
Investigational Site Number 1560030, Lianyungang
Investigational Site Number 1560013, Jinan
Investigational Site Number 1560027, Tianjin
Investigational Site Number 1560026, Hangzhou
Investigational Site Number 1560007, Hangzhou
Investigational Site Number 1560017, Chongqing
Investigational Site Number 1560006, Changsha
Investigational Site Number 1560012, Xi'an
Investigational Site Number 1560020, Kunming
Investigational Site Number 1560029, Ningbo
Investigational Site Number 1560024, Shenzhen
Investigational Site Number 1560025, Yancheng
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY